Disclosure. A New Partnership. Objectives 03/27/2014. What is the main way you have obtained information about the 2013 ACC/AHA Cholesterol Guideline?
|
|
- Duane Matthews
- 5 years ago
- Views:
Transcription
1 Disclosure Lindsey Clark, PharmD, BCPS Cardiology-Medicine Pharmacy Specialist University of Cincinnati Medical Center April 10, 2014 I, Lindsey Clark, do not have a financial interest or affiliation with one or more organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. What is the main way you have obtained information about the 2013 Cholesterol Guideline? A. Reading the full report B. Skimming the report C. Attending a continuing education session D. Through the news media E. Summaries on professional websites or journal articles F. Other The most surprising aspect of the 2013 cholesterol guidelines for me: A. The 10-year atherosclerotic cardiovascular disease risk () calculator B. The transition away from treat-to-target C. The recommendations for primary and/or secondary prevention D. The recommendations for monitoring requirements for drug therapy E. thing, I predicted all of the recommendations through my previous knowledge of the evidence F. I haven t read the guidelines yet, so I m not sure what changed Objectives Discuss major changes and controversies with the new hyperlipidemia guidelines Identify four major statin benefit groups Make recommendations for monitoring and optimizing therapy for hyperlipidemia 2002: National Cholesterol Education Program by Adult Treatment Panel (ATP) III A New Partnership We cannot be a strong nation unless we are a healthy nation. And so we must recruit knowledge and science in the service of national strength. F.D. Roosevelt 2011: Institute of Medicine issues report on systematic reviews and trustworthy clinical guidelines October 8, 2013: announce partnership with for development of five clinical practice guidelines Apply treatment recommendations to patient care 2008: convened ATP IV to perform systematic evidence reviews and develop critical questions = National Heart, Lung, and Blood Institute ACC = American College of Cardiology AHA = American Heart Association June 19, 2013: announces they will refocus efforts vember 12, 2013: Practice Guidelines Released Obesity Lifestyle Interventions CV Risk Assessment Cholesterol Guidelines 1
2 Independent Contractors Task Force Adult Treatment Panel IV The Expert Panel Formal Peer Review Endorsed by: American Society for Preventive Cardiology American Pharmacists Association American Association of Cardiovascular and Pulmonary Rehabilitation Association of Black Cardiologists Preventive Cardiovascular Nurses Association WomenHeart: The National Coalition for Women with Heart Disease Who: Scope of the Guideline Blood cholesterol treatment of adults ( 21 years of age) For those most likely to benefit What: Strong evidence-based foundation for the treatment of cholesterol for primary and secondary prevention of atherosclerotic cardiovascular disease () When: Released in vember 2013 Literature covered through 2011, unless otherwise noted in methodology Will begin continual review and update in 2014 How: Intended for primary care providers and specialists concerned with prevention Designed to be easy to use in the clinical setting to facilitate the implementation of a strategy of risk assessment and treatment Limitations Recognized by the Expert Panel Significant departure from current strategies Overwhelming body of evidence came from statin randomized controlled trials (RCTs) Recommendations focused on groups that are well represented in RCTs or validated meta-analyses (MAs) Guidelines do not answer questions regarding complex lipid disorders Refer to clinicians with lipid expertise for management Recommendations designed to inform clinical judgment, not replace it Transitioning from s and Quality of Evidence to Class and Level of Evidence s and Quality of Evidence: Strength of Recommendations A Strong recommendation B Moderate recommendation C Weak recommendation D Recommendation against E Expert opinion N recommendation for or against Quality of Evidence Type of Evidence Available High (H) Well-designed, well-executed RCTs that adequately represent populations to which the results are applied and directly assess effects on health outcomes. MAs of such studies. Moderate (M) RCTs with minor limitations affecting confidence in, or applicability of, the results. Well-designed, well-executed nonrandomized controlled studies and well-designed, wellexecuted observational studies. MAs of such studies. Low (L) RCTs with major limitations. nrandomized controlled studies and observational studies with major limitations affecting confidence in, or applicability of, the results. Uncontrolled clinical observations without an appropriate comparison group (e.g., case series, case reports). Physiological studies in humans. MAs of such studies. Insufficient (I) Insufficient evidence Class and Level of Evidence: Definitions Atherosclerotic Cardiovascular Disease () Acute coronary syndromes or a history of myocardial infarction (MI) Stable or unstable angina Coronary or other arterial revascularization Stroke or Transient Ischemic Attack (TIA) Peripheral arterial disease All presumed to be of atherosclerotic origin 10-Year Risk In ages predicts 10 year risk of: nfatal MI Coronary heart disease death nfatal and fatal stroke 2
3 Age (Years) Reassess every 4-6 years Reassess every 4-6 years Reassess every 4-6 years Major Benefit Groups Benefit Groups 190 ( if not Estimated 10-y risk 7.5% Estimate 10-y Risk Prevention Benefit of Therapy Less Clear in Benefit Groups 190 Why treat a patient with a normal LDL? Estimate 10-y Risk Prevention Benefit of Therapy Less Clear in ( if not Estimated 10-y risk 7.5% Why treat a patient with a normal LDL? CTT 2010: s for Patients with rmal LDL Meta-analysis of 26 RCTs (170,000 participants) 21 trials statin vs. control 5 trials more vs. less statin Results: Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke With each 1.0 mmol/l reduction reducing the annual rate of these major vascular events by just over a fifth. There was no evidence of any threshold within the cholesterol range studied, suggesting that reduction of LDL cholesterol by 2 3 mmol/l would reduce risk by about 40 50%. Cholesterol Treatment Trialists (CTT) Collaboration. Lancet 2010; 376: LDL 1 mmol/l = 39 LDL 1.8 mmol/l = 70 Why treat a patient with a normal LDL? Benefit Groups LDL C eligibility criteria versus age eligibility criteria in placebo groups for primary-prevention RCTs. > < 40 JUPITER CARDS AFCAPS MEGA 190 Estimate 10-y Risk Why was 10 year risk lowered from 10% to 7.5%? What is the 10 year risk? ( if not Estimated 10-y risk 7.5% LDL-C () Prevention Benefit of Therapy Less Clear in 3
4 What is the 10 year risk? 10 Year Risk Calculator New Pooled Cohort Equations Goal: Accurately identify higher risk individuals with hope to focus on those most likely to benefit Estimates 10-year risk in both white and black men and women, years of age, who do not have clinical Age is heavily weighted Person aged 70 years (risk 7.5%) without other risk factors will receive statin treatment on the basis of age alone Risk assessment tools or novel risk markers examined or recommended have not been formally evaluated Why was risk lowered to 7.5%? Why was risk lowered to 7.5%? HIGH INTENSITY STATIN TREATMENT Assumes a 45% relative risk reduction in from high intensity statin treatment NNT to prevent 1 event varies by baseline estimated 10-year risk NNH based on 3 excess cases of incident diabetes* per 100 individuals treated with statins for 10 years. CTT 2012: s in Low Risk Patients Major Vascular Events: Major coronary events (non-fatal MI or coronary death) Strokes Coronary revascularizations Results: For risk 10%, each 1 mmol/l (1 mmol/l = 39 ) reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years Meta-analysis of 27 RCTs 22 trials statin vs. control 5 trials more vs. less statin Five categories of baseline 5-year major vascular event risk on control therapy What if 10 year risk is < 7.5%? If a risk-based treatment decision is uncertain, consider assessing one or more of the following to inform treatment decision making: 5 to <7.5% 10-year risk Primary 160 or other evidence of genetic hyperlipidemias Family history of premature High sensitivity C-reactive protein 2 mg/l Coronary artery calcium score 300 Agatston units or 75th percentile for age, sex, and ethnicity Ankle-brachial index <0.9 Lifetime risk of Cholesterol Treatment Trialists (CTT) Collaborators. Lancet 2012; 380:
5 Reassess every 4-6 years Benefit Groups Medication Strategies to Reduce 190 Where are goal lipid levels? ( if not Treat-to-cholesterol target Lower cholesterol is better Risk-based treatment approaches Treat level of risk Lifetime Risk Estimate 10-y Risk Estimated 10-y risk 7.5% Fixed Doses of Cholesterol Lowering Drugs to Reduce Risk of Prevention Benefit of Therapy Less Clear in Definitions of Therapy High-Intensity Therapy Daily dose lowers LDL C by approximately 50% Atorvastatin mg Rosuvastatin 20 (40) mg Moderate-Intensity Therapy Low-Intensity Therapy Daily dose lowers LDL C by Daily dose lowers LDL C approximately 30% to <50% by <30% Atorvastatin 10 (20) mg Simvastatin 10 mg Rosuvastatin (5) 10 mg Pravastatin mg Simvastatin mg Lovastatin 20 mg Pravastatin 40 (80) mg Fluvastatin mg Lovastatin 40 mg Pitavastatin 1 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 2 4 mg Bold = evaluated in RCTs and demonstrated reduction in major adverse cardiovascular events Italics = not tested in RCTs reviewed Percent reduction in LDL C can be used as an indication of response and adherence to therapy, but is not in itself a treatment goal Problems with Treat to Target Secondary prevention If patient achieves an LDL C of 78 on a dose of 80 mg of atorvastatin, he/she is receiving evidence-based therapy. Family History with LDL C >190 This patient may only achieve an LDL C of 120 despite use of 3 cholesterol-lowering drugs. Although this patient may have fallen short of the 100 goal, if starting from an untreated LDL-C level of ~ they have decreased their LDL C by >50%. Type 2 diabetes Those with diabetes often have lower LDL-C levels than those without diabetes, "goal" directed therapy often encourages use of a lower statin dose than is supported by RCTs, and nonstatin drugs may be added to address low HDL C or high triglycerides, for which RCT evidence of an event reduction is lacking. Critical Question 1 Reviewed 19 RCTs Supported conceptually by an extrapolation of observational studies and observational data from RCTs data were identified regarding treatment or titration to a specific LDL-C goal in adults with clinical Majority of studies used a single fixeddose to lower LDL-C levels 4S trial: 37% had the dose of simvastatin raised from 20 mg to 40 mg per day to achieve a total cholesterol level <200 mg/day Unable to find any RCTs that: Evaluated titration of all individuals in a treatment group to specific LDL-C targets Compared two LDL-C treatment targets Reported on-treatment non-hdl-c levels Trials reviewed for CQ1 4D A Z ACCORD ALLIANCE ASPEN AURORA CARE CORONA GREACE HATS HPS IDEAL LIPID LIPS MIRACL MUSHASHI- AMI PROVE-IT SPARCL TNT 5
6 Reassess every 4-6 years CQ1: Excerpt from Full Panel Report Critical Question 2 Reviewed 6 RCTs Four studies used fixed-dose statin therapy AFCAPS/TexCAPS trial 50% of participants lovastatin dose was raised from 20 mg to 40 mg/day to achieve an LDL-C <110 MEGA trial the dose of pravastatin could be uptitrated from 10 mg to 20 mg to achieve a total cholesterol <220 RCTs found: Evaluated titration of all individuals in a treatment group to specific LDL-C targets Compared 2 LDL-C treatment targets Reported on-treatment non-hdl-c levels Trials reviewed for CQ2 AFCAPS/ TexCAPS ASPEN Comments Age Moderate Intensity Age yrs with LDL-C <140 mg/dl if prior MI Or < 160 if not AURORA Aged Included primary and secondary prevention patients CARDS JUPITER Diabetics only Age Moderate Intensity Individuals with LDL- C <130 mg/dl MEGA Age CQ2: Excerpt from Full Panel Report What happened to goal lipid levels? The panel makes no recommendations for or against specific LDL-C or non-hdl-c targets for the primary or secondary prevention of. COR = Class of Recommendation LOE = Level of Evidence COR LOE N N/A N/A EVIDENCE STATEMENTS Data are not available regarding treatment or titration to a specific LDL-C goal in adults with CHD/CVD. The panel found insufficient evidence to support setting LDL-C goals in CHD/CVD patients. We did not identify any trials in adults with CHD/CVD reporting mean or median ontreatment non-hdl-c levels in adults with CHD/CVD. LDL-C goals <130 or <100 in patients without CHD/CVD. Randomized trial data are not available regarding dose titration to achieve a specific LDL-C goal. There was insufficient evidence in women without CHD/CVD to evaluate the reduction in CVD risk with achieved LDL-C levels <130 or <100. Can we give up Treat-to-Target? Benefit Groups Deliberated extensively over a 3-year period Many clinicians use targets RCT evidence shows events are reduced by using the maximum tolerated statin intensity Compared fixed doses of statins with placebo or untreated controls Compared fixed doses of higher-intensity statins with moderate-intensity statins AIM-HIGH: Niacin therapy added to vs. Alone Additional niacin therapy DID NOT further reduce risk in individuals treated to LDL C levels of Implications of treating to an LDL-C goal may mean: Suboptimal dose of statin is used because the goal has been achieved Adding a non- to achieve a specific target Addition of non- that has not been shown to reduce Prevention Benefit of Therapy Less Clear in 190 Estimate 10-y Risk If we don t treat to target is any monitoring required? ( if not Estimated 10-y risk 7.5% 6
7 Reassess every 4-6 years Efficacy Monitoring of s targets? Safety? Adherence to medication and lifestyle, therapeutic response to statin therapy, and safety should be regularly assessed. Fasting lipid panel performed within 4 to 12 weeks after initiation or dose adjustment, and every 3 to 12 months thereafter. The maximum tolerated intensity of statin should be used in individuals for whom a high- or moderate-intensity statin is recommended, but not tolerated. In individuals who have a less-than-anticipated therapeutic response or are intolerant of the recommended intensity of, the following should be performed: Reinforce medication adherence. Reinforce adherence to intensive lifestyle changes. Exclude secondary causes of hyperlipidemia. It is reasonable to use the following as indicators of anticipated therapeutic response to the recommended intensity of. Focus is on the intensity of the. As an aid to monitoring: High-intensity : LDL C reduction of 50% from the untreated baseline Moderate-intensity : average LDL C reduction of 30 to <50% from the untreated baseline LDL C levels and percent reduction are to be used only to assess response to therapy and adherence. They are not to be used as performance standards. Decreasing the statin dose may be considered when 2 consecutive values of LDL C levels are <40. COR LOE A I A B I B A I A E IIa B C IIb C Safety Monitoring of s To maximize the safety of statins, selection of the appropriate statin and dose in men and non-pregnant/non-nursing women should be based on patient characteristics, level of risk, and potential for adverse effects. Moderate-intensity should be used in individuals in whom high-intensity would otherwise be recommended when characteristics predisposing them to statinassociated adverse effects are present. CK should not be routinely measured in individuals receiving. Baseline measurement of CK is reasonable for individuals believed to be at increased risk for adverse muscle events based on a personal or family history of statin intolerance or muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk for myopathy. Baseline measurement of hepatic transaminase levels (ALT) should be performed before initiating. During, it is reasonable to measure hepatic function if symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of the skin or sclera). COR LOE A I B A III: Benefit A E IIa C B I B E IIa C Safety Monitoring of s Individuals receiving should be evaluated for newonset diabetes mellitus according to the current diabetes screening guidelines. Those who develop diabetes mellitus during should be encouraged to adhere to a heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue to reduce their risk of events. For individuals taking any dose of statins, it is reasonable to use caution in individuals : >75 years of age Taking concomitant medications that alter drug metabolism Taking multiple drugs Taking drugs for conditions that require complex medication regimens For individuals presenting with a confusional state or memory impairment while on, it may be reasonable to evaluate the patient for nonstatin causes, such as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in addition to the possibility of adverse effects associated with statin drug therapy. COR LOE B I B E IIa C E IIb C intensity Moderateintensity statin vs. placebo/control High-intensity vs. moderateintensity statin High-intensity (rosuvastatin) vs. placebo Risk with s Fewer major CVD events/1,000 individuals treated for 1 year vs. placebo Excess cases of incident diabetes per 1,000 individuals treated for 1 year vs. placebo NNT per year NNH per year , Lipid Panel LFTs CK Myopathy Symptoms Blood glucose Cognitive Function Overview of Monitoring Requirements Baseline Every 1 3 months after initiation/dose change or Every 3 12 months As ly Indicated Benefit Groups 190 Estimate 10-y Risk Where is non-statin therapy? ( if not Estimated 10-y risk 7.5% Prevention Benefit of Therapy Less Clear in 7
8 Critical Question 3 Interventions evaluated included pharmacotherapy with single-drug therapies or combination-drug therapies with any drug therapy used for treating blood cholesterol s Fibrates (fenofibrate, gemfibrozil) Nicotinic acid (niacin in immediate-, slow-, or extended-release form) Bile acid sequestrants Ezetimibe Omega-3 fatty acids (also called marine fatty acids, including eicosapentaenoic acid alone, docosahexanoic acid alone, eicosapentaenoic acid plus docosahexanoic acid, and alpha-linolenic acid). There were no outcomes identified for plant sterols, sterol esters, stanols, or stanol esters Xuezhikang Extract from red yeast Chinese rice One RCT from China was not available in the United States during the timeframe for evidence review, so no recommendations were made regarding its use n- RCTs Evaluated nstatin drug Niacin Cholestyramine Ezetimibe Gemfibrozil Fenofibrate EPA EPA = eicosapentaenoic acid nstatin vs. placebo CDP (men with HLD and CHD) LRC (primary prevention in men with HLD) HHS (in men with HLD) VA-HIT (men with hx of CHD) FIELD (with diabetes) - Primary Preventinon; Secondary Prevention Coadministered and nonstatin vs. placebo HATS (with simvastatin in pts with CHD) SEAS (with simvastatin in pts with aortic stenosis) SHARP (with Simvastatin in pts with CKD) Coadministered statin and nonstatin vs. statin AIM-HIGH (vs. Simvastatin in pts with CHD) ACCORD (vs. simvastatin in pts with DM) JELIS (vs. pravastatin in Japanese adults with HLD) Where is non-? For individuals 21 years of age with an untreated primary LDL C 190, after the maximum intensity of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL C. Evaluate the potential for risk reduction benefits, adverse effects, drug-drug interactions, and consider patient preferences. In individuals at higher risk receiving the maximum tolerated intensity of who continue to have a less-than-anticipated therapeutic response, addition of a nonstatin cholesterol-lowering drug(s) may be considered if the risk-reduction benefits outweigh the potential for adverse effects. Preference should be given to nonstatin cholesterol-lowering drugs shown to reduce events in RCTs. In individuals who are candidates for statin treatment but are completely statin intolerant, it is reasonable to use nonstatin cholesterol-lowering drugs that have been shown to reduce events in RCTs if the risk-reduction benefits outweigh the potential for adverse effects. COR LOE E IIb C IIb IIa C B Questions for Future Guidelines Treatment of hypertriglyceridemia Use of non-hdl-c in treatment decision-making Whether on-treatment markers such as Apo B, Lp(a), or LDL particles are useful for guiding treatment decisions Best approaches to using noninvasive imaging for refining risk estimates to guide treatment decisions How lifetime risk should be used to inform treatment decisions and the optimal age for initiating to reduce lifetime risk of ; Subgroups of individuals with heart failure or undergoing hemodialysis that might benefit from Long-term effects of statin-associated new onset diabetes and management Efficacy and safety of statins in patient groups excluded from RCTs to date (e.g., HIV positive or solid organ transplant) Role of pharmacogenetic testing Patient Case #1 63 M s/p STEMI 2 weeks ago PMH: HTN, HLD SH: Smoker Medications: Atorvastatin 80 mg QHS Aspirin 81 mg daily Clopidogrel 75 mg daily Lisinopril 5 mg daily Metoprolol 25 mg PO BID Patient was previously on simvastatin 80 mg QHS, but discontinued 2 weeks after starting due to leg cramps. Prior to that he had tolerated simvastatin 40 mg QHS He is concerned about his previous reaction and would like to decrease the atorvastatin to 20 mg QHS. How do you respond to his concern? A. RCTs of high intensity vs. moderate intensity have not shown significant difference in outcomes., we can decrease to atorvastatin 20 mg QHS. B. Meta-analyses of RCTs support the use of high intensity statin over moderate intensity. The best choice is to stay on atorvastatin 80 mg. C. Due to previous reaction he should be followed with creatine kinase values when his lipids are checked at each visit for the first year. D. Although his liver panel was normal in the hospital, he should have an ALT done at each subsequent visit. E. Check his LDL-C to determine if a dose reduction is appropriate. Adapted from Prevention Guidelines Vignettes: Vignettes.pdf 8
9 Patient Case #2 Patient Case #3 44 F with 10-year history of type 2 diabetes PMH: HTN, microalbuminuria SH: non-smoker FH: diabetes BP 134/78 BMI 36 LDL-C 95 Triglycerides 350, HDL-C 38 HgbA1c 7.5% Medications: Dietary management Metformin 1000 mg BID Omega-3 fatty acid capsule with 840 mg of EPA and DHA. Lisinopril/HCTZ What is the next step for management? A. LDL < 100 so she is at goal. B. She should start simvastatin 20 mg and fenofibrate 160 mg daily. C. To reduce her risk of an event, increase omega-3 to 4 capsules daily. D. If she does not want to start a statin, a bile acid sequestrant is the next best choice for her. E. Her 10-year risk should be calculated to determine if high- or moderate-intensity statin should be initiated. 60 AAF asking whether she should take a statin to reduce risk of stroke, but worried about statin causing diabetes. FH: mother diabetes & stroke at 62 SH: nonsmoker BP 142/88 on 2 medications HDL 55 ; TG 100 ; LDL 125 Blood glucose 109 mm/dl; HgbA1c 5.9% According to pooled cohort equation for African American women her estimated 10 year risk is 8.7% Which statement is true? A. She should focus on lifestyle change to improve her risk factors because lifestyle has been shown to reduce events more than statin therapy. B. Risk of progression to diabetes with a statin outweighs any risk reduction benefits from. She should defer a statin at this time. C. She should start a moderate or high intensity statin. D. A high sensitivity C-reactive protein> 2 would be needed before making a recommendation. Adapted from Prevention Guidelines Vignettes: Vignettes.pdf Adapted from Prevention Guidelines Vignettes: Vignettes.pdf Top 10 Key Points to Remember 10. A new Expert Panel 9. Lifestyle modification remains a critical component to therapy 8. Pooled cohort equations for 10 year risk 7. Greater emphasis on RCTs and meta-analysis 6. Four major statin benefit groups - excluding heart failure and dialysis - LDL Diabetics age years with - n-diabetics, age 40-75, and 10 Year Risk 7.5% 5. recommendations for people not in the four major benefit groups 4. Monitoring requirements 3. Less emphasis on non-statin therapies 2. Say Goodbye to Treat to Target & Lower is Better 1. New Goal: Treat to Level of risk with Appropriate Intensity of Therapy Lindsey Clark, PharmD, BCPS Cardiology-Medicine Pharmacy Specialist University of Cincinnati Medical Center April 10,
Pharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationVincent J. Caracciolo, MD FACC FOMA May 2014
Vincent J. Caracciolo, MD FACC FOMA May 2014 Goals of the Guidelines National Heart, lung and Blood Institute ( NHLBI) collaborated with ACC/AHA to develop guidelines a.) assess CV risk, b.) lifestyle
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More information2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2
2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2 GOALS ACC/AHA as publisher of guidelines Determining which patients are appropriate for statin therapy The treatment
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationCardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Cardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation,
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationObservations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA
Observations on US CVD Prevention Guidelines Donald M. Lloyd-Jones, MD ScM FACC FAHA What are Guidelines? Evidence Base for Guidelines Tricoci, JAMA 2009 Evidence Base for Guidelines Tricoci, JAMA 2009
More informationAcute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPrevention Updates and Paradigm Shifts
Prevention Updates and Paradigm Shifts Andrew Freeman, MD, FACC Director of Clinical Cardiology and Operations National Jewish Health Assistant Professor of Medicine National Jewish Health and University
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationMajor recommendations for statin therapy for ASCVD prevention
2013 A/AHA Guidelines holesterol Rx to Reduce ASVD Risk in Adults Major recommendations for statin therapy for ASVD prevention *% in LDL can be used as indication of response & adherence to Rx but is not
More informationCPE Session 7. Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction
CPE Session 7 Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction Saturday, April 25, 2015 ACPE UAN 0128-0000-15-027-L01-P 1.0
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationLDL and the Benefits of Statin Therapy
LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration
More informationObjec ves To discuss the process of formulation of guidelines and how this may differ among professional societies 5/14/15
Kellie McLain, NP- C, CLS Medical University of South Carolina Cardiology Division Seinsheimer Cardiovascular Prevention and Lipid Program May 29 th, 2015 Objecves To discuss the process of formulation
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationNEW GUIDELINES FOR CHOLESTEROL
NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationUnderstanding US Lipid Guidelines-2013:
Presentation to NLA Symposium: May 3 2014 Understanding US Lipid Guidelines-2013: Neil J. Stone MD, MACP, FACC Bonow Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Il
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationDisclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?
Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationLipid Update AHA/ACC 2013 Guidelines
Lipid Update AHA/ACC 2013 Guidelines Jessica M. Fleagle (Bender) D.O. University of Missouri School of Medicine Assistant Professor of Clinical Medicine Associate Program Director of Medicine Residency
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More information2.3 CONTACT HOURS. Managing. By Kristine Anne Scordo, PhD, RN, ACNP-BC, FAANP
2.3 CONTACT HOURS 2.3 CONTACT HOURS Managing hyperlipidemia The updated cholesterol treatment guidelines Abstract: The ACC/AHA 2013 cholesterol treatment guidelines focus on lowering the risk of heart
More informationUpdate on Hyperlipidemia Guidelines
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Update on Hyperlipidemia Guidelines Drew Keister MD Lehigh Valley Health Network, Drew_M.Keister@lvhn.org Follow this and
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationTHE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL
THE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL Anne Carol Goldberg, MD, FACP, FAHA, FNLA Associate Professor of Medicine Washington University School of Medicine National Lipid Association
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationDyslipidemia: What s New In The Guidelines?
1 Dyslipidemia: What s New In The Guidelines? Rhonda Cooper-DeHoff, Pharm D, MS Associate Professor Colleges of Pharmacy and Medicine University of Florida Disclosures 2 No actual or perceived conflicts
More informationSpeaker Disclosure. Pharmacist Objectives. Path to New Hypertension (HTN) Guidelines. Overview of New HTN Guidelines 8/21/2014
Speaker Disclosure Erica Pearce, Pharm.D. declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants,
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More information